AstraZeneca

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology.

CEO

Pascal Soriot

CEOPascal Soriot

Employees

96,100

Employees96,100

Headquarters

Cambridge, Cambridgeshire

HeadquartersCambridge, Cambridgeshire

Founded

1913

Founded1913

Employees

96,100

Employees96,100

AZN Key Statistics

Market cap

318.70B

Market cap318.70B

Price-Earnings ratio

30.97

Price-Earnings ratio30.97

Dividend yield

1.54%

Dividend yield1.54%

Average volume

2.15M

Average volume2.15M

High today

$205.26

High today$205.26

Low today

$202.00

Low today$202.00

Open price

$202.64

Open price$202.64

Volume

466.22K

Volume466.22K

52 Week high

$212.71

52 Week high$212.71

52 Week low

$122.48

52 Week low$122.48

Stock Snapshot

AstraZeneca(AZN) stock is priced at $205.12, giving the company a market capitalization of 318.7B. It carries a P/E multiple of 30.97 and pays a dividend yield of 1.5%.

On 2026-04-09, AstraZeneca(AZN) stock traded between a low of $202.00 and a high of $205.26. Shares are currently priced at $205.12, which is +1.5% above the low and -0.1% below the high.

AstraZeneca(AZN) shares are trading with a volume of 466.22K, against a daily average of 2.15M.

During the past year, AstraZeneca(AZN) stock moved between $122.48 at its lowest and $212.71 at its peak.

AZN News

TipRanks 23h

AstraZeneca Extends Fasenra’s Runway With New Long-Term Safety Study

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper de...

TipRanks 23h

ESPERANZA Update: Real-World Data Study Could Broaden AstraZeneca’s T-DXd Cancer Opportunity

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisio...

TipRanks 2d

AstraZeneca: Oncology and CVRM Momentum, Pipeline Progress, and FX Tailwinds Underpin Raised £165 Price Target and Buy Rating

In a report released today, Sarita Kapila from Morgan Stanley reiterated a Buy rating on AstraZeneca, with a price target of p16,500.00. Unlock hedge fund-leve...

Analyst ratings

81%

of 31 ratings

Buy

80.6%

Hold

9.7%

Sell

9.7%

More AZN News

TipRanks 6d

Innate Pharma Balances Pipeline Progress With Cash Strain

Innate Pharma S.A. ((FR:IPH)) has held its Q4 earnings call. Read on for the main highlights of the call. End of Quarter Sale - 50% Off TipRanks Unlock hedge fu...

TipRanks 6d

AstraZeneca Completes Early Obesity Trial for AZD6234, Nudging Long-Term Growth Hopes

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisio...

TipRanks 7d

AstraZeneca’s New Cancer Combo Trial Signals Steady Progress in Antibody Drug Conjugates

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper de...

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.